Great Grand Care

Great Grand Care is a clinical-stage biotechnology company based in Taiwan that specializes in the development of advanced cell therapies for oncology and regenerative medicine. The company's core focus is its proprietary GGC-NK platform, which produces highly potent Natural Killer (NK) cells designed to target and eliminate solid tumors and hematological malignancies. Additionally, Great Grand Care is advancing a pipeline of mesenchymal stem cell (MSC) therapies aimed at treating degenerative diseases and inflammatory conditions. The company operates state-of-the-art GTP (Good Tissue Practice) laboratories to ensure the quality and safety of its cell products. Through strategic clinical collaborations with major medical centers, Great Grand Care is working to bring next-generation immunotherapy to the global market.